The dual role of heat shock protein 70 (HSP70), as antigenic peptide chaperone and danger signal, makes it especially important in dendritic cell (DC)-based vaccination. In this study, we investigated the impacts of apoptotic transgenic MCA/HSP tumor cells expressing HSP70 on DC maturation, T-cell stimulation and vaccine efficacy. We found that DCs with phagocytosis of MCA/HSP in early phase of apoptosis expressed more pMHC I complexes, stimulated stronger cytotoxic T lymphocyte (CTL) responses (40% specific killing at an E:T cell ratio of 50) and induced immune protection in 90% of mice against MCA tumor cell challenge, compared with 25% specific CTL killing activity and 60% immune protection seen in mice immunized with DC with phagocytosis of MCA/HSP in late phase of apoptosis (Po0.05). Similar results were confirmed in another EG7 tumor model also expressing HSP70. Taken together, our data demonstrate that HSP70 on apoptotic tumor cells stimulate DC maturation, and DC with phagocytosis of apoptotic tumor cells expressing HSP70 in early phase of apoptosis more efficiently induced tumor-specific CTL responses and immunity than DCs with phagocytosis of apoptotic tumor cells in late phase of apoptosis. These results may have an important impact in designing DC-based antitumor vaccines.
Introduction
Dendritic cells (DCs) are the most powerful antigenpresenting cells (APC) in initiation of antitumor immune responses by presenting tumor-associated antigens (TAA) to T cells and stimulating tumor-specific T-cell responses. 1 DCs can acquire soluble tumor antigens (Ags) from living tumor cells by macropinocytosis or Fc-or lectin receptormediated endocytosis, or phagocytose dying (apoptotic or necrotic) tumor cells. [2] [3] [4] Dying tumor cells have been shown to be a source of TAA for processing and presentation by DC, both experimentally and clinically.
Apoptotic cell death is a common way for a cell to die, and self-nonself discrimination would fail if dying cells triggered an immune response against themselves. 5 Cells that undergo apoptosis are readily engulfed by DC 6 via a V b 5 , CD36 7 and phosphatidylserine (PS) receptor, 8 and subsequently, DCs efficiently present the Ags of apoptotic cells to class I-restricted cytotoxic T lymphocytes (CTLs). 6 Cells dying of necrosis are phagocytosed through interaction of CD91 9 and LOX1 10 receptors with heat shock proteins (HSP) expressed on necrotic tumor cells. The uptake of dying tumor cells has been shown to impact both DC maturation and DC immunogenicity.
Controversy still exists with respect to the optimal form of killed tumor cells for stimulating effective immune priming and antitumor activity in DC-based vaccine strategies. Early reports showed that DC that phagocytosed apoptotic cells could exclusively cross-present Ags to CTLs. 6 DC pulsed with apoptotic tumor cells induced a strong Ag-specific T-cell response in vitro, and when injected into mice, such pulsed DC induced tumor-specific cytotoxic T-cell responses and long-term protection from parental tumor challenge. 11 It was later shown that necrotic, but not apoptotic, cells could induce DC maturation to elicit immunity. 12, 13 In another report, however, both apoptotic and necrotic tumor cells could equivalently induce DC-mediated immune priming and antitumor therapeutic efficacy. 14 More recently, it has further been shown that DC charged with apoptotic tumor cells induced long-lived protective CD4 þ and CD8 þ T-cell immunity 15 and apoptotic, but not necrotic, tumor cells are efficient vaccines in vivo. 16 Apparently contradicting these results, it has also been reported that the presence of apoptotic cells during macrophage activation increases their secretion of anti-inflammatory mediators 17 and decreases their secretion of proinflammatory cytokines, 18 and that apoptotic cells are actually able to induce suppression of inflammatory responses and tolerance. 19, 20 In line with this notion, there is evidence for the lack of immunogenicity 21 or reduced immunogenicity of apoptotic tumor cells as compared with viable counterparts. 22 Given the predominance of apoptotic cell death in most common cancer treatment regimens, 23 it is important to know whether the enhanced tumor Ag presentation associated with DC presenting these Ags will enhance the development of immunity, or of immune tolerance to the tumor.
We previously demonstrated that apoptotic tumor cells with secondary necrosis induced DC maturation, and vaccination of DC with phagocytosis of these apoptotic tumor cells in late phase of apoptosis stimulated an efficient antitumor immunity. 24 However, the potential critical role of HSP70 expression in this model has not been investigated. In some reports, necrotic tumor cells expressing HSP70 can promote DC maturation whereas apoptotic cells cannot, 12, 13 it is possible that the effects of dying tumor cells on DC maturation and function may depend not only on the type of cell death (apoptosis versus necrosis) but also on the phase of tumor cell apoptosis (early apoptosis versus secondary necrosis) as well as the association of HSP70 expression. In this study, we selected two tumor cell lines, EG7 and MCA26, with and without endogenous expression of HSP70. We generated tumor cell apoptosis in their early or late phases of apoptosis with different irradiation doses in vitro. We then investigated the impacts of these apoptotic tumor cells on DC maturation, T-cell stimulation and vaccine efficiency. We found that apoptotic EG7 tumor cells expressing HSP70 in early phase of apoptosis more efficiently induced DC maturation and vaccine efficiency than those in late phase of apoptosis. To confirm this, we further transfected MCA-26 tumor cells with the HSP70 gene, and investigated the effect of HSP70 expression in the induction of efficient antitumor immunity by vaccination of DC with phagocytosis of these HSP70-expressing tumor cells in early or late phase of apoptosis.
Materials and methods
Cell lines, antibodies, cytokines, peptides and animals EL4, a T-cell lymphoma line of C57BL/6 mouse (H-2K b ) origin, its ovalbumin (OVA) gene-transfected cell line EG7, and colon cancer cell line MCA26 (MCA) and the B-cell lymphoma cell line A20 of BALB/c mouse (H-2K d ) origin were all obtained from American Type Culture Collection (Rockville, MD). EL4 and MCA cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM, Gibco, Gaithersburg, MD) and 10% fetal calf serum (FCS), whereas EG7 tumor cells were kept in the above medium plus G418 (0.5 mg/ml, Gibco). Monoclonal rat anti-mouse major histocompatibility complex (MHC) II, ICAM-1, CD80, CD86 and HSP70 antibodies as well as the fluorescein isothiocyanate (FITC)-anti-HSP70 antibody were all purchased from Pharmingen (San Diego, CA). FITC-conjugated goat anti-rat IgG antibodies were purchased from Bio/Can Scientific (Mississauga, Ontario, Canada). Phycoerythrin (PE)-labeled H-2K b /OVA 257À264 tetramer, FITC-labeled rat anti-mouse CD8 antibody and streptavidin-conjugated phecoerythrin-Texas Red-X (ECD) were obtained from Beckman Coulter (San Diego, CA). Recombinant mouse interleukin (IL)-4 and granulocyte macrophage colony stimulation factor (GM-CSF) were purchased from Endogen (Woburn, MA). The MHC class I (H-2K b )-restricted OVAI peptide (OVA 257À264 , SIINFEKL) 25 was synthesized by Multiple Peptide Systems (San Diego, CA). The anti-H-2Kb/OVAI (pMHC I) complex antibody was obtained from Dr Germain (National Institute of Health, Bethesda, MD).
26 Female C57BL/6 (H-2K b ) and BALB/c (H-2K d ) mice were obtained from Charles River Laboratories (St Laurent, Quebec, Canada). OVAspecific T-cell receptor (TCR)-transgenic OT I mice on C57BL/6 background were obtained from the Jackson Laboratory (Bar Harbor, MA). All mice were housed in the animal facility at the Saskatoon Cancer Center; with all animal experiments carried out in accordance with the Canadian Council for Animal Care guidelines.
Construction of expression vector pcDNA-HSP70
Total RNA was extracted from EG7 tumor cells using the RNeasy Mini Kit (Qiagen, Mississauga, Canada). A 2.0 kb cDNA fragment coding for the open reading frame of HSP70 molecule was cloned by reverse transcription polymerase chain reaction (RT-PCR) from a cDNA library of EG7 cells using PFU polymerase (data not shown). Two PCR primers were used, both the sense primer (5 0 -AGCCT TCCAG AAGCA GAGCG-3 0 ) and the antisense primer (5 0 -GCAGC TATCA AGTGC AAAGA GTCTG-3 0 ). The cloned cDNA fragment of HSP70 was ligated into the pCR2.1 vector (Invitrogen, Carlsbad, CA) to form pCR2.1/HSP70. The HSP70 gene sequence was verified by the dideoxy nucleotide sequencing method. The HSP70 gene fragment (EcoRV/BamH1) was further cloned into the plasmid pcDNA3.1 (Invitrogen, San Diego, CA) to form the expression vector pcDNA-HSP70.
Generation of transfected cell line MCA-26/HSP70
Twenty million MCA26 cells were resuspended in 0.7 ml phosphate-buffered saline (PBS) and mixed with 0.3 ml PBS containing 10 mg pcDNA-HSP70 DNA. Tumor cells were transfected with pcDNA-HSP70 or the control pcNDAneo using a Bio-Rad gene pulser (Bio-Rad Lab, Mississauga, Ontario, Canada) with parameters of 300 V and 125 mF capacitance as previously described. 27 Transfected cells were selected for growth in a medium containing 4 mg/ml G418. The selected clones MCA26/ HSP70 (MCA/HSP) and the control MCA26/neo (MCA/ neo) were then analyzed for HSP70 expression by Western blot and flow cytometry.
Generation and analysis of apoptotic tumor cells Apoptosis of EG7, MCA and MCA/HSP tumor cells was generated by in vitro irradiation with 1000 and 5000 rad, respectively, cultured in DMEM plus 10% fetal calf serum (FCS) for 12 and 48 h, and then harvested for electronmicroscopy and flow cytometric analysis or DC phagocytosis. For flow cytometric analysis, the apoptotic tumor cells were analyzed using anti-HSP70 antibody and Annexin V-FITC (PharMingen, San Diego, CA) by flow cytometry. For further confirmation of apoptosis, the apoptotic tumor cells were analyzed by using the Annexin V-FITC Apoptosis Detection kit (PharMingen, San Diego, CA) according to the protocol of the manufacture's manuals. When using the Annexin V-FITC Apoptosis Detection kit, apoptotic/necrotic tumor cells were incubated with Annexin V-FITC in a binding buffer containing propidium iodide (PI) and analyzed by flow cytometry.
Preparation of bone marrow (BM)-derived DCs A previously described procedure was used for generation of DCs from bone marrow (BM) culture. 24 Briefly, BM cells prepared from femurs and tibias of normal C57BL/6 mice were depleted of red blood cells with 0.84% ammonium chloride and plated in DMEM plus 10% FCS, GM-CSF (10 ng/ml) and IL-4 (10 ng/ml) on day 1. On day 3, nonadherent granulocytes, and B and T lymphocytes were gently removed, and fresh media were added. On day 5, loosely adherent proliferating DC aggregates were dislodged and replated. On day 7 of culture, released, mature, nonadherent cells with the typical morphological features of DCs were harvested and used for in vitro phenotypic analysis as well as for peptide pulsing or co-cultivation with apoptotic tumor cells.
Analysis of DC phagocytosis
Apoptotic tumor cells were labeled with CFSE as previously described. 29 To evaluate DC phagocytosis of apoptotic tumor cells, DCs were cultivated with CFSE-labeled apoptotic tumor cells at a ratio of 3:1 in the culture medium containing GM-CSF (10 ng/ml) and IL-4 (10 ng/ml) at 371C overnight. DCs were harvested, purified with Ficoll-Paque gradient and then analyzed by flow cytometry and electronmicroscopy.
Immunofluorescence analysis of DCs with phagocytosis of apoptotic tumor cells For phenotypic analysis, DCs with phagocytosis of apoptotic tumor cells in early and late phases of apoptosis were termed DC EG7ÀE , DC EG7ÀL , DC MCAÀE , DC MCAÀL , DC MCA/HSPÀE and DC MCA/HSPÀL , respectively, and subjected to flow cytometric analysis using a panel of antibodies specific for MHC class II, CD54, CD80 and CD86. Briefly, DCs were incubated with each of the above antibodies (5 mg/ml) on ice for 30 min. After three washes with PBS, cells were incubated with FITCconjugated goat anti-rat IgG antibody (1:60) on ice for another 30 min. After three washes with PBS, cells were then analyzed by flow cytometry. Isotype-matched monoclonal antibodies were used as controls.
Western blot analysis
Western blot analysis using tumor cell lysates were performed as previously described. 27 Briefly, the protein extract was prepared from tumor cells using the extraction buffer containing 125 mM tris (hydroxymethyl) aminomethane, 0.05% sodium dodecyl sulfate and 10% bmercaptoethanol. Cell extracts were harvested from the supernatant after centrifugation at 1000g for 5 min. The supernatants containing the protein samples were electrophoresed through 10% gels and transferred onto nitrocellulose papers; blots were blocked using PBS containing 10% bovine serum albumin (BSA) and incubated with the anti-HSP70 antibody, followed by the goat anti-rat IgG antibody conjugated with peroxidase. Detection of HSP70 was accomplished by using enhanced chemiluminescence reagent according to the manufacturer's protocol (New England Nuclear Life Science Products, Boston, MA).
Mixed lymphocyte reaction (MLR)
Spleens were removed from C57BL/6 mice for preparation of the splenic lymphocyte suspension and 0.84% ammonium chloride was used to lyse red cells. T cells were obtained from the splenic lymphocytes by using nylon wool columns (C&A Scientific Inc., Manassas, VA) to deplete residual APC. The primary MLRs were performed as described previously. 24 Briefly, irradiated BALB/c or C57BL/6 mouse BM-derived DC with phagocytosis of apoptotic MCA or EG7 tumor cells (4000 rad, 0.4 Â 10 5 cells/well) were incubated in graded doses with a constant amount (1 Â 10 5 cells/well) of allogeneic T cells of the C57BL/6 or BALB/c mouse in each well of 96-well culture plates, respectively. After 3 days, T-cell proliferation was measured by adding 1 mCi/ well of [ T-cell proliferation assays Naı¨ve OVA-specific CD8 þ T cells were isolated from OT I mouse spleens, and enriched by passage through nylon wool columns. CD8 þ cells were then purified by negative selection using anti-mouse CD4 (L3T4) paramagnetic beads (DYNAL Inc, Lake Success, NY) to yield populations that were . Spontaneous counts per minute (CPM) released in the absence of effector cells were less than 10% of specific lysis. The maximal CPMs were released by adding 1% Triton X-100 to wells in experiments.
DC vaccines
For evaluation of antitumor immunity, mice were vaccinated subcutaneously (s.c.) with 0.5 Â 10 6 DCs, with phagocytosis of apoptotic MCA, MCA/HSP or EG7 tumor cells. Ten days after final immunization, mice (n ¼ 10 per group) were challenged by s.c. injection of 0.5 Â 10 6 MCA or EG7 tumor cells. Animal mortality and tumor growth were monitored daily for up to 10 weeks; for humanitarian reasons, all mice with tumors that achieved a size of 1.5 cm in diameter were killed.
Results

Tumor cell apoptosis induced by in vitro irradiation
To study the potential effect of HSP70 in DC-mediated antitumor immunity, we selected two tumor cells lines EG7 and MCA-26 (MCA), with and without expression of HSP70 (Figure 1a) , respectively. In addition, we constructed an expression vector pcDNA-HSP70 and further transfected MCA-26 tumor cells with this vector. As shown in Figure 1a , the transfected tumor cell line MCA-26/HSP70 (MCA/HSP) expressed HSP70 after vector transfection. Both MCA/HSP and EG7 tumor cells expressed HSP70, but not PS. The HSP70 expression of MCA/HSP and EG7, but not MCA and EL4 tumor cells, was further confirmed by Western blot analysis (Figure 1b) . MCA, MCA/HSP and EG7 tumor cells were irradiated with 5000 and 1000 rad for induction of tumor cell apoptosis. The apoptotic tumor cells in early and late phase of apoptosis express PS (early apoptosis marker) detected by Annexin V-FITC and HSP70 (late apoptosis marker) detected by anti-HSP70 antibody. 24, 28 As shown in Figure 2a and EL4 using the extraction buffer containing 125 mM tris aminomethane, 0.05% sodium dodecyl sulfate and 10% b-mercaptoethanol. Cell extracts were electrophoresed through 10% gels and transferred onto nitrocellulose papers. The transferred nitrocellulose paper strips were incubated with the anti-HSP70 antibody, followed by the goat anti-rat IgG antibody conjugated with peroxidase. Detection of HSP70 was accomplished by using enhanced chemiluminescence reagent. (Figure 2c ) when they were irradiated and cultured for 12 and 48 h, respectively.
HSP70 enhances efficiency of DC vaccines
Enhanced maturation of DCs with phagocytosis of apoptotic tumor cells expressing HSP70 DCs used in this study were derived from mouse bone marrow cells cultivated in culture medium in the presence of IL-4 and GM-CSF. These DCs showed (i) a typical morphologic characteristic of DCs with numerous dendrites and (ii) the expression of MHC II, ICAM-1, CD80 and CD86 (data not shown), indicating that they are mature DCs. 30 After physical contact with apoptotic MCA tumor cells in culture, DCs displayed phagocytosed apoptotic tumor cell in the cytoplasm (Figure 3 ). After physical contact with CFSE-labeled apoptotic MCA-E (Figure 4c ), indicating that DC EG7ÀE may be able to more efficiently cross-present OVA to T cells than DC EG7ÀL .
Enhanced CD8
þ T-cell proliferation induced by DCs with phagocytosis of HSP70-expressing tumor cells in early phase of apoptosis DCs are potent stimulators of primary MLR and induce the proliferation of allogeneic CD8 þ T cells in vitro. 31 To assess this function, we compared DCs that had phagocytosed apoptotic tumor cells with or without HSP70 expression with regard to their effect on primary allogeneic MLR. As shown in Figures 5a and b , DC MCAÀL or DC MCA/HSPÀE , which had phagocytosed apoptotic MCA-L or MCA/HSP-E tumor cells expressing HSP70, more strongly stimulated allogeneic C57BL/ 6T-cell proliferation than DC MCAÀE with phagocytosis of MCA-E without HSP70 expression (Po0.05), indicating that DCs with phagocytotsis of apoptotic MCA tumor cells in late phase of apoptosis are more immunogenic than DC with phagocytosis of apoptotic tumor cells in early phase of apoptosis, when MCA tumor cells do not express HSP70. To assess the stimulatory effect of DC EG7ÀE and DC EG7ÀL on allogeneic BALB/c T cells, we also performed MLR. As shown in Figure 5c , DC EG7ÀE and DC EG7ÀL with phagocytosis of HSP70-expressing apoptotic EG7 tumor cells stimulated allogeneic T-cell proliferation to a similar extent. To assess the stimulatory effect of DC EG7ÀE and DC EG7ÀL on OVA-specific CD8 þ T cells, we further performed OVA-specific T-cell proliferation assay using CD8 þ T cells derived from OVA-specific TCR-transgenic OTI mice. As shown in Figure 5d , DC EG7ÀE stimulated stronger OVAspecific T-cell proliferation in vitro than DC EG7ÀL (Po0.05). To confirm it, we further conducted an in vivo T-cell proliferation experiment using OVA-specific tetramer staining. As shown in Figure 6 , vaccination of DC EG7ÀE and DC EG7ÀL stimulated 2.5 and 1.5% OVAspecific CD8 þ T cells in total CD8 þ T-cell population by OVA-specific tetramer staining, indicating that DCs with phagocytosis of apoptotic EG7 tumor cells expressing HSP70 in early phase of apoptosis are more immunogenic than DCs with phagocytosis of apoptotic EG7 tumor cells in late phase of apoptosis.
þ CTL responses induced by DC with phagocytosis of HSP70-expressing tumor cells in early phase of apoptosis To examine the cytotoxic effect of CTL responses, we performed chromium release assays. Splenocytes from mice immunized with DC MCAÀE , DC MCAÀL , C MCA/ HSPÀE , DC MCA/HSPÀL , DC EG7ÀE and DC EG7ÀL were cocultured with irradiated MCA or EG7 tumor cells. 
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After 4 days in culture, T lymphocytes were harvested and analyzed by flow cytometry. These T lymphocytes, which were mostly CD8 þ T cells as analyzed by flow cytometry (data not shown), were used as effector cells in a chromium release assay. As shown in Figure 7a , T lymphocytes derived from mice vaccinated with DC MCAÀL , which had phagocytosed apoptotic MCA tumor cells expressing HSP70, displayed significantly stronger, cytotoxicity to MCA tumor cells (34% specific killing at an E:T cell ratio of 50) than those of mice vaccinated with DC MCAÀE with phagocytosis of HSP70-negative apoptotic MCA tumor cells (20% specific killing at an E:T cell ratio of 50) (Po0.05). However, the T lymphocytes derived from mice vaccinated with DC MCA/HSPÀE had slightly, but significantly stronger cytotoxicity to MCA tumor cells than DC MCA/HSPÀL (Po0.05) (Figure 7b ). As shown in Figure 7c , DC EG7ÀE also induced significantly more efficient T cell cytotoxicity to EG7 tumor cells (47% specific killing at an E:T cell ratio of 25) than DC EG7ÀL (33% specific killing at an E:T cell ratio of 25) (Po0.05). Our data indicate that vaccination of DCs that had phagocytosed HSP70-expressing apoptotic tumor cells in early phase of apoptosis can induce more efficient tumor-specific CTL responses than DCs with phagocytosis of HSP70-expressing apoptotic tumor cells in late phase of apoptosis or apoptotic tumor cells in early phase of apoptosis, but without HSP70 expression. The above CTL responses were against MCA and EG7, but not against A20 and EL4, indicating that they are MCA and EG7 tumor specific. (Figure 8b) . Interestingly, similar results were obtained from groups of mice vaccinated with DC EG7ÀE and DC EG7ÀL . As shown in Figure 8c , DC EG7ÀE vaccination protected 10 out of 10 mice (100%) from EG7 tumor challenge, whereas DC EG7ÀL vaccination resulted in 70% protection. Our data thus clearly indicate that the vaccination of DCs that had phagocytosed HSP70-expressing apoptotic tumor cells in early phase of apoptosis induces the strongest antitumor immunity in both MCA and EG7 tumor models.
Discussion
Radiation has been found to induce tumor cell apoptosis through both the death receptor and the mitochondrial pathways, [32] [33] [34] which is favorable for tumor antigen release. Several phases have been characterized in programmed cell death 35, 36 from the early phase of PS exposure on the cell surfaces to the late phase, defined as secondary necrosis, and characterized by the cell membrane damage revealed by using PI staining 36 and the expression of HSP. 37 Heat shock proteins belong to a family of chaperone proteins, the key elements in the protein-folding machinery of the cells.
Srivastava and Amato 38 first identified HSP as the component of tumor lysates, which protected mice from a subsequent tumor challenge. Initial studies focused on vaccination with endogenous HSP purified from tumor cells. Despite encouraging results with this strategy in mouse models 39, 40 and in humans, 41, 42 purification of HSP from tumor cells is a labor-intensive and timeconsuming procedure. Other strategies involve purification of recombinant HSP from bacterial or mammalian 
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T Chan et al cells. 43, 44 Drawbacks of these strategies include the requirement for known tumor Ags to be associated with HSP and the contamination of immunogenic bacterial products. 45, 46 Vaccination of tumor cells engineered to express or secrete HSP preserves the primary advantage of purified HSP (i.e., the broad spectrum of chaperoned HSP70 enhances efficiency of DC vaccines T Chan et al tumor peptides that include unknown tumor antigens) without the cumbersome procedure of HSP purification. However, transfection of tumor cells with HSP coding sequences has given contradictory results. In some experimental models, overexpression of HSP increased immunogenicity of transfected tumor cells, 47, 48 whereas in other models, it increased tumorigenicity. 49 This discrepancy can be explained by the protective activity of HSP, which helps to prevent cells from triggering apoptosis in response to stressful stimuli. 50 To avoid the possible protumorigenic activity of transfected HSP, their intracellular localization has been modified. The cytosolic HSP70 and endoplasmic reticulum-resident gp96 have been converted into transmembrane proteins. 51, 52 These modified forms of HSP maintained the ability to activate the immune responses against parental tumor cells. In all of the above strategies, tumor antigens are taken up by DC and cross-presented to T cells, resulting in antitumor immune responses.
Weeks after Tumor Inoculation
An alternative is the direct use of DC-mediated antitumor vaccine. In vitro-generated DCs can phagocytose apoptotic tumor cells when culturing DCs with apoptotic tumor cells. These DC with phagocytosis of apoptotic tumor cells can thus present tumor antigens to T cells and induce antitumor immunity. We previously demonstrated that apoptotic tumor cells with secondary necrosis induced DC maturation and vaccination of DCs, with phagocytosis of these apoptotic tumor cells in late phase of apoptosis stimulating an efficient antitumor immunity. 24 However, the potential critical role of HSP70 expression in this model has not been investigated. In some reports, necrotic tumor cells expressing HSP70 can promote DC maturation whereas apoptotic cells cannot, 12, 13 which leaves the possibility that the effects of dying tumor cells on DC maturation and function may depend not only on the type of cell death (apoptosis versus necrosis) but also on the phase of tumor cell apoptosis (early apoptosis versus secondary necrosis) as well as the association of HSP70 expression. In this study, we also demonstrated that apoptotic tumor cells (in late phase of apoptosis) expressing HSP70 stimulate DC maturation after DC phagocytosis of these apoptotic tumor cells, which is consistent with some previous reports. [53] [54] [55] DCs, with phagocytosis of apoptotic tumor cells (in late phase of apoptosis) expressing HSP70 induced stronger antitumor immunity than DC with phagocytosis of tumor cells in early phase of apoptosis, which is consistent with a recent report from our group. 28 More interestingly, we demonstrated that apoptotic tumor cells expressing HSP70 in early phase of apoptosis more efficiently induce tumor-specific CTL responses and vaccine efficiency than those in late phase of apoptosis in two MCA/HSP and EG7 tumor models. This is because HSP70 can trigger a danger signal by binding to DC receptors such as TLR4 56, 57 and CD14 58 through nuclear factor (NF)kB to upregulate co-stimulatory molecules of DCs and induce DC secretion of proinflammatory cytokines. 13 The dual role of HSP70 as antigenic peptide chaperone 59 and danger signal 13 thus makes them especially important for DC-based vaccination in induction of antitumor immune responses. Second, DCs with phagocytosis of apoptotic EG7 tumor cells expressing HSP70 in early phase of apoptosis can present more pMHC I complexes to T cells, as shown in this study. The controversial reports have shown that necrotic tumor cells induced stronger tumor-specific CTL responses than apoptotic tumor cells in some reports, 12, 13 whereas, in some other tumor models, 16 DC charged with apoptotic, but not necrotic, tumor cells induced efficient vaccines in vivo. Therefore, these controversial findings may be derived from the different tumor models used in these studies, in which tumor cells may or may not express HSP70, and the HSP70 expression in early or late phase of apoptosis may also vary in different types of tumor cells.
Taken together, our data demonstrate that HSP70 on apoptotic tumor cells stimulate DC maturation, and DC with phagocytosis of apoptotic tumor cells expressing HSP70 in early phase of apoptosis induce more efficient tumor-specific CTL responses and immunity than DC with phagocytosis of apoptotic tumor cells in late phase of apoptosis. These results may have an important impact in designing DC-based antitumor vaccines.
